Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Go back to Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer| (NASDAQ: CRBP) | Delayed: 7.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.88 | 52 Week High | $10.78 | |||
| Open | $7.88 | 52 Week Low | $1.01 | |||
| Day High | $7.88 | P/E | N/A | |||
| Day Low | $7.88 | EPS | $0.00 | |||
| Volume | 249 | |||||
